<DOC>
	<DOCNO>NCT02611258</DOCNO>
	<brief_summary>Pathophysiology Cushing 's Syndrome ( CS ) cardiomyopathy yet unclear specific treatment indicate . It already demonstrate positive impact phosphodiesterase type 5A ( PDE5A ) inhibition several model cardiomyopathy model endocrine cardiomyopathy due type 2 diabetes mellitus . In patient diabetic cardiomyopathy demonstrate improvement cardiac kinetic , geometry performance parameter reduction ambulatory measurement waist circumference . This represent first study evaluate heart remodel performance change metabolic/immunological/molecular parameter 5-months Tadalafil 20 mg Cushing 's Syndrome cardiomyopathy . The propose research test whether phosphodiesterase 5A inhibition could become new target anti-remodeling drug discover molecular pathway affect class drug network circulate marker ( miRNA ) early diagnosis Cushing 's Syndrome cardiomyopathy . The investigator hypothesize : - signal molecule cGMP cAMP could underlie hypertrophic/profibrotic trigger related model endocrine cardiomyopathy chronic inhibition PDE5 , activate cGMP signal pathway , could improve cardiac remodel due CS ; - PDE5 inhibition could role lipolytic regulation ; - neuroendocrine ( e.g . natriuretic peptide ) metabolic marker chemokines ( e.g . MCP-1 , TGF-ß ) might relate leave ventricular remodel CS ; - neuroendocrine ( e.g . natriuretic peptide ) , metabolic marker chemokines ( e.g . MCP-1 , TGF-ß ) relate cardiac disease CS ; - miRNA expression [ miR-208a , 499 , 1 , 133 , 126 , 29 , 233 , 222 , 4454 ] might relate leave ventricular remodel CS ;</brief_summary>
	<brief_title>Endocrine Cardiomyopathy Cushing Syndrome : Response Cyclic GMP PDE5 inhibitOrs</brief_title>
	<detailed_description>Mechanisms action evolutionary progression Cushing 's Syndrome ( CS ) cardiomyopathy yet well elucidate specific treatment identify . Our study aim characterize CS cardiomyopathy term measure cardiac kinetic performance parameter ( tag Cardiac Magnetic Resonance Imaging ) , fibrosis ( T1-mapping technique ) . Our study evaluate PDE5A inhibition could become new target antiremodeling drug CS treat patient developed cardiac hypertrophy and/or diastolic dysfunction independently CS care accord current guideline . The investigator also explore potential mechanism action PDE5Ai : exerted cardiac tissue directly contemporary also secondary pathway ( analyze vascular , endothelial , metabolic marker ) . A multidisciplinary approach allow identify cluster cardiovascular ( NT-ProBNP , TGFb , MCP1 ) metabolic index , oxidative stress marker ( iNOS , COX2 , ROS , RANTES ) miRNAs , whose variation analyze together CS cardiomyopathy parameter measure CMR 2D-echocardiography . The Primary Objective evaluate effect PDE5Ai Left Ventricular ( LV ) remodeling ( kinetic geometry parameter ) cine cardiac magnetic resonance ( CMR ) tag technique contrast-enhanced and/or 2D echocardiography Tissue Doppler Imaging speckle track patient CS cardiomyopathy Secondary Objectives : - measure effect PDE5Ai LV fibrosis T1-mapping CMR baseline PDE5Ai administration . - measure effect PDE5Ai cardiac performance cine CMR 2D echocardiography Tissue Doppler Imaging speckle track baseline PDE5Ai administration . - measure effect PDE5Ai circulate cardiac-inflammatory-metabolic-endothelial molecular marker - measure effect bone body composition Patients screen time 0 . Follow visit take place every 4 week treatment 5 month 1 month end treatment . Diagnostic procedure include : - physical examination measurement anthropometric parameter ( weight , waist circumference , hip circumference ) vital sign ( blood pressure , heart rate ) ; - blood sample assess glucose lipid metabolism , liver , renal , hematopoietic coagulative function , thyroid androgen hormone , ACTH UFC , inflammatory parameter ( cytokine , monocyte subpopulation ) microRNA ; - SF36 , FSFI ( woman ) , IEFF e IPSS ( men ) questionnaire ; - cardiac exam , electrocardiogram echocardiogram ; - MOC DEXA ; - magnetic resonance imaging ( MRI ) contrast-enhanced cardiac : T1-mapping assess cardiac fibrosis ; tag evaluate kinetic parameter ( torsion ) ; This pilot study proof-of-concept , 10 patient sufficient detect effect PDE5Ai cardiac remodel CS cardiomyopathy . Estimating 80 % drop-out study due complexity CS relate neuro-psychiatric involvement , 18 CS patient enrol . All variable test normality . Statistical analyzes perform use SPSS 18.0 . The comparison treatment make non parametric Wilcoxon test . The investigator calculate confidence interval prevalence effect measure χ2 test Fisher exact test . The correlation perfomed Rho di Spearman .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cushing Syndrome</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>age &gt; 18 yr ; patient ( men woman ) previous diagnosis Cushing Syndrome ( CS ) , surgically and/or clinically treat accord current guideline , stable parameter CS disease last 3 month , concomitant cardiac hypertrophy and/or diastolic dysfunction develop independently CS care detect 2D echocardiography ; urinary free cortisol ( UFC ) level normal range sex age ; normal blood pressure control hypertension use thiazolidinediones , spironolactone ; nitrate , doxazosin , terazosin e prazosin ; current use PDE5 inhibitor previous ( wash two month least ) ; congenital valvular cardiomyopathy ; recent ischemic heart disease revascularization myocardial infarction ( MI ) ; contraindication tadalafil use ( hypersensitivity tadalafil , nitrate use , severe cardiovascular disorder unstable angina severe heart failure , severe hepatic impairment , blood pressure &lt; 90/50 mmHg , recent history stroke myocardial infarction know hereditary degenerative retinal disorder retinitis pigmentosa ) ; contraindication CMR .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Left Ventricular Hypertrophy</keyword>
	<keyword>Diastolic Dysfunction</keyword>
	<keyword>Myocardial Fibrosis</keyword>
	<keyword>Cushing 's Syndrome</keyword>
</DOC>